GLOW Blend
Also referenced as: GLOW 70 mg, GHK-Cu + BPC-157 + TB-500 blend
A three-component research blend of GHK-Cu, BPC-157 and TB-500, typically supplied as a 70 mg vial and discussed in skin and tissue research contexts.
- Evidence grade
- DPreclinical Research
Preclinical Research
- Regulatory status
- Research Use Only
No component of this blend is an approved injectable medicine for the purposes discussed. BPC-157 is prohibited in sport. Sold as research-use-only material.
- Human data
- No
No registered clinical trials identified
- Last reviewed
- September 14, 2026
Overview
GLOW is a vendor-coined name for a blend of GHK-Cu, BPC-157 and TB-500. It is not a pharmaceutical product and the name carries no regulatory meaning.
Component ratios vary between suppliers, so a 70 mg total does not describe a standard formulation. Anyone using a blend for research should confirm the stated split and check it against a certificate of analysis.
Interest centres on skin appearance, collagen biology and soft-tissue repair, all extrapolated from laboratory and animal work on the individual peptides.
Why It's Being Studied
- Copper-peptide effects on collagen and extracellular matrix in skin models.
- Angiogenesis and granulation in wound-healing models.
- Cell migration during tissue remodelling.
- Cosmetic and recovery claims, which run well ahead of the evidence.
Mechanism of Action
The three peptides are each studied for skin and tissue repair in laboratory work. The blend simply puts them in one vial.
GHK-Cu is a copper-binding tripeptide reported to modulate metalloproteinase and collagen gene expression and to influence antioxidant enzyme systems in dermal fibroblast cultures. BPC-157 has reported VEGF-A and eNOS-linked angiogenic activity in rodent injury models. TB-500 is an actin-sequestering fragment of thymosin beta-4 that promotes cell migration. There is no published pharmacology for the three combined.
Research Areas & Routes Studied
- Skin collagen and appearance
- Wound healing
- Soft-tissue repair
- Hair follicle biology
- Subcutaneous injection (research)
- Topical formulations for GHK-Cu in cosmetic literature
Evidence Summary
Component peptides are supported by laboratory and animal research in skin and tissue models. The blend itself has no human trial data.
Human clinical evidence
- No controlled human trials of the blend exist. Human evidence for GHK-Cu is limited to small cosmetic studies of topical formulations.
In-vitro studies
- Fibroblast culture work reports changes in collagen and matrix gene expression with GHK-Cu.
Animal studies
- Rodent wound and injury models underpin the repair claims for BPC-157 and thymosin beta-4 fragments.
Anecdotal / community information
- Almost all information about GLOW blends is community-generated, describing skin and recovery impressions.
Reported Adverse Events in Research
- Injection-site reactions, redness and irritation are commonly reported for copper peptides.
- No systematic human safety data exist for injected GHK-Cu or for the blend.
- Theoretical concern about angiogenic stimulation of abnormal tissue.
- Copper exposure from repeated injection has not been characterised.
Limitations of Current Evidence
- Component ratios are not standardised between suppliers.
- Topical cosmetic data for GHK-Cu do not support injected use.
- Three-component blends make adverse events impossible to attribute.
Why It Is Used
- Skin & Hair
Skin, Hair and Wound Healing
The KLOW and GLOW stacks are the most-discussed cosmetic peptide combinations. Here is what each ingredient actually has behind it.
Read the case study
Research References
- In-vitro study
GHK-Cu peptide in skin regeneration and gene expression
- Animal study
BPC-157 in tissue healing: animal studies
- Narrative review
Thymosin beta-4 and tissue repair